| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA833: Zanubrutinib for treating Waldenström's macroglobulinaemia |
|
Medicine details |
|
| Medicine name | zanubrutinib (Brukinsa®) |
| Formulation | hard capsule |
| Reference number | 3688 |
| Indication | Monotherapy for the treatment of adult patients with Waldenström’s macroglobulinaemia (WM) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy. |
| Company | BeiGene |
| BNF chapter | Malignant disease & immunosuppression |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 07/01/2022 |
| NICE guidance | TA833: Zanubrutinib for treating Waldenström's macroglobulinaemia |